Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail

Pancreatic cancer (PC) remains one of the most challenging diseases, with a very poor 5-year overall survival of around 11.5%. Kirsten rat sarcoma virus (KRAS) mutation is seen in 90%-95% of PC patients and plays an important role in cancer cell proliferation, differentiation, metabolism, and surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Elhariri, Ahmed, Alhaj, Ahmed, Ahn, Daniel, Sonbol, Mohamad Bassam, Bekaii-Saab, Tanios, Wu, Christina, Rutenberg, Michael Scott, Stauffer, John, Starr, Jason, Majeed, Umair, Jones, Jeremy, Borad, Mitesh, Babiker, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494558/
https://www.ncbi.nlm.nih.gov/pubmed/37700806
http://dx.doi.org/10.5306/wjco.v14.i8.285
Descripción
Sumario:Pancreatic cancer (PC) remains one of the most challenging diseases, with a very poor 5-year overall survival of around 11.5%. Kirsten rat sarcoma virus (KRAS) mutation is seen in 90%-95% of PC patients and plays an important role in cancer cell proliferation, differentiation, metabolism, and survival, making it an essential mutation for targeted therapy. Despite extensive efforts in studying this oncogene, there has been little success in finding a drug to target this pathway, labelling it for decades as “undruggable”. In this article we summarize some of the efforts made to target the KRAS pathway in PC, discuss the challenges, and shed light on promising clinical trials.

Ejemplares similares